☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Quetiapine SPC update

The manufacturer of quetiapine (Seroquel®) has written to healthcare professionals advising of an update to the summary of product characteristics for both the standard and prolonged release tablets.

The letter advises that the update to the special warnings and precautions section includes advice on:

  • Weight gain - should be monitored and managed as clinically appropriate.
  • Hyperglycaemia - hyperglycaemia and/or development or exacerbation of diabetes has been reported rarely but has been fatal in some cases. It is recommended that patients are monitored for observed for signs and symptoms of hyperglycaemia or worsening diabetes control and managed as appropriate.
  • Metabolic Risk - it is suggested that the observed changes in weight, blood glucose and lipids may result in an increased metabolic risk. This should be managed as clinically appropriate.

Action: The metabolic risks posed by second generation (atypical) antipsychotics are well known. This update reminds clinicians of the need to monitor for these effects and intervene where appropriate.

Share 'Quetiapine SPC update' by emailShare 'Quetiapine SPC update' on FacebookShare 'Quetiapine SPC update' on TwitterShare 'Quetiapine SPC update' on LinkedInShare 'Quetiapine SPC update' on reddit


No Comments to “Quetiapine SPC update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.